Novartis’ Vaccines division (now a part of GlaxoSmithKline), an innovative producer of vaccines including Pediatric, Specialty and Meningitis vaccines, went live with OMP Plus in January 2015.
The focus of the implementation was on a holistic, advanced optimization of the global network containing five production facilities. To achieve this goal, OMP Plus generates, in just a matter of minutes, a multi-layered capacity constrained production plan in response to forecasted demand. In addition, biopharmaceutical complexities are taken into account. These include shelf life, production facilities with cross-contamination risk limitations, internal and governmental QA release times and campaign planning for seasonal products.
OMP Plus allows collaborative scenario comparison resulting in prioritization between the different Novartis Vaccines product families.
Amir Reichman, Head of Resource Planning and Strategy, states: “The introduction of OMP Plus drastically reduced the time it takes us to generate a plan, increased our ability to rapidly respond to changes in inputs, generate and discuss scenarios and allowed us to ensure an optimized plan is created.”
Dirk Van Ginderachter, Senior Project Manager at OM Partners, says: “We are pleased to see that OMP Plus outperforms all success criteria in this project. The speed of implementation with a time line of only five months between start of the analysis phase and go-live also proves our capabilities and experience in the pharmaceutical industry.”
About Novartis Vaccines (part of GSK)
Novartis Vaccines provides innovative vaccines and a wide range of conventional products to combat viral and bacterial diseases across the globe including vaccinations For Bacterial Meningitis (MenB, MenC and MenA,C,W,Y combined), Pediatric (D,P,T, Hib combo vaccines) and Travel (Tick Born Encephalitis, Rabies). Their mission is to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.
The division was acquired by GlaxoSmithKline in March 2015.
Dirk Van Ginderachter, Senior Project Manager
Phone: +32 3 650 22 73